AGV Discovery offers services in chemistry, cell biology, in vitro screening, rational drug design, outsourcing and consultancy. AGV Discovery is a pharmaceutical company that specializes in the rational design and early development of drug candidates.

68 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Easily detect your biological nanoparticles A spin-off from the Institut d'Optique Graduate School, Université Paris-Saclay, UNVEIL is a deeptech start-up that facilitates the development and production of biologics (drugs derived from living organisms, such as messenger RNA vaccines, as opposed to chemical ones). These biologics (gene therapy, RNA vaccines, etc.) are transported to the target site in the human body by nanometric vectors (viruses or lipid nanoparticles). R&D and production of these biomedicines is hampered by the lack of effective technology to measure vector loading. UNVEIL has developped an optical, label-free instrument capable of quickly and easily measuring nanovector loading …

86 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression. Gene Therapy

96 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

InnaVirVax is a French privately-owned biopharmaceutical company dedicated to the development of a cutting edge discovery in the field of therapy/prevention and prognostic of AIDS and HIV infection, other infectious diseases, and cancer therapies. InnaVirVax is developing product candidates resulting from a beakthrough discovery, made at Inserm, the French Medical research council, the AP-HP, the largest hospital in Europe, and University Pierre et Marie Curie in Paris. Based on a new paradigm (i.e. the understanding of the mechanism responsible for the decline of the CD4+ T lymphocytes (CD4) in HIV-infected patients), the products currently developed by InnaVirVax will allow the …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering RNA cell therapy for autoimmune disease Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis with plans to initiate a Phase 2 trial in myositis. For more information, please visit www.cartesiantherapeutics.com. Immunotherapy, Oncology, Molecular Biology, Immunology, Myasthenia Gravis, ARDS, Cell Therapy, NETs, Gene Therapy, Cancer Research, multiple myeloma, SLE, mRNA, CAR-T, Systemic lupus erythematosus, Autoimmunity, Autoimmune Disease, and Lupus

293 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

less complexity. more biology. At Chromodynamics, we are on a mission to deliver instruments that eliminate guesswork from drug development and prescription. Our unique technology allows for an enormous improvement in speed, efficacy, and cost with which exciting new treatments like immunotherapy are developed. We have been recognised as one of the most promising startups in the Eindhoven Brainport region and are expanding our team to ramp up our product development. Imaging systems, Multispectral imaging, Real-time analysis, Chemical imaging, Spectroscopy, Scientific instruments, Contract research, and Data analysis

931 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Redirecting Immune Memory from Pathogens or Childhood Vaccines to Target Cancer VerImmune is advancing Anti-tumor Immune Redirection (AIR): A Breakthrough Therapy that Redirects Pre-Existing Immune Memory from Childhood Vaccination or Infection to Fight Cancer

125 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Apriori Bio is working to create a world where humanity is protected against viral threats. Apriori is working to create a world where humanity is protected against viral threats. Our pioneering approach centers on a unique technology platform, which allows us to survey the entire landscape of existing and potential viral variants to design new vaccines and antibody drugs against the most threatening variants. Octavia can also inform public health policy in real time by predicting the impact of emerging variants. Apriori was founded in 2020 in Flagship Labs, a unit of Flagship Pioneering.

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Immunic (Nasdaq: IMUX) is a late-stage biotechnology company developing novel oral therapies for neurologic diseases. Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. Privacy Policy: https://imux.com/privacy-policy/

100 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Precision Vaccines Company Belyntic creates novel vaccines for viral diseases with unmet medical need. We have developed and validated a new platform technology, that generates self-adjuvant synthetic long peptides for a safe and durable induction of cellular immunity. Drug development, Cellular immunity, and Platform technology

260 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A WuXi Advanced Therapies company, based in Oxford, UK. OXGENE, a WuXi Advanced Therapies (WuXi ATU) company, based in Oxford, UK, provides cell and gene therapy pioneers around the world with the technologies, automation platforms and service solutions they need to come first in the race to deliver ground-breaking therapeutics. OXGENETM is headquartered in Oxford, UK. For additional information, please visit our website. PRODUCTS: Largest collection of standardised plasmids on the market and SERVICES: DNA Services, Protein Production Services, Virus Services, Cell Line Development Services.

113 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Reimagining known biology to deliver high impact medicines Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist and preclinical GIPR modulator programs. For more information, please visit: www.ternspharma.com. Pharmaceuticals, Liver Disease, Life Sciences, BioPharmaceuticals, CML, Oncology, and HemOnc

343 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has over 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s …

75 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Science to Transform Lives Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr Biotechnology, Cancer, Oncology, Infectious Diseases, Autoimmune Diseases, T Cell Receptor, Immunotherapy, ImmTAX, ImmTAC, ImmTAV, and ImmTAAI

267 similar entities Type: Startup Activities: deeptech hrtech biotech Technologies: Synthetic Biology

OZ Biosciences creates, develops and commercializes life sciences reagents specialized in transfection and transduction OZ Biosciences is a product development company that creates, develops and commercializes delivery systems of bioactive materials (DNA, siRNA, proteins, antibodies...), intended for the worldwide scientific community and pharmaceutical industries. Our mission is to assist scientists to accelerate the rhythm of discoveries by offering them technologically advanced tools such as transfection reagents and other life science research products. Principal innovations are based on proprietary technologies such as Magnetofection (magnetic-assisted transfection or infection), Magneto-Biolistic, transfection reagents, transduction tools, mRNA and lipids-based delivery systems (LNP). Specialized and expert …

90 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

VectorBuilder is a global leader in gene delivery technologies. As a trusted partner for thousands of labs and biotech/pharma companies across the globe, VectorBuilder offers a full spectrum of gene delivery solutions covering virtually all research and clinical needs from bench to bedside. VectorBuilder is the future of gene delivery. Our mission is to provide end-to-end solutions for all gene delivery needs spanning both research and therapy. We strive to offer innovative and high-quality products and services while maintaining rapid turnaround and exceptional affordability. Our “white-glove” customer care is supported by a PhD-level team with decades of collective experience to …

75 similar entities Type: Startup Activities: deeptech manufacturing Technologies: Synthetic Biology

Clinical-stage company developing proprietary protein superglue vaccines against infectious diseases, including CMV, EBV Spun out of the University of Oxford in 2017, SpyBiotech is a clinically validated vaccine company built on proprietary protein "superglue" technology. It snaps antigens onto a vaccine scaffold in a single step, giving us a faster, more reliable way to build robust vaccines. We apply this across two complementary platforms. Our virus-like particle (VLP) platform is Phase I-validated, and our viral vector platform extends the same plug-and-play approach to more targets. Together they form a flexible engine for vaccines against established and emerging diseases. Two lead …

72 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Engineering Hope MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicine company with a broad pipeline of late-stage clinical programs supported by end-to-end manufacturing capabilities. MeiraGTx has an internally developed manufacturing platform process, internal plasmid production for GMP, two GMP viral vector production facilities as well as an in-house Quality Control hub for stability and release, all fit for IND through commercial supply. MeiraGTx has core capabilities in viral vector design and optimization and a potentially transformative riboswitch gene regulation platform technology that allows for the precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing …

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Standard BioTools delivers the leading proteomic and multi-omic solutions that enable researchers to discover unique biological insights not accessible by other technologies. Mass Cytometry, Tissue Imaging, NGS Library Prep, Genotyping, Gene Expression, Copy Number Variation, Real-Time PCR, and Single-Cell Genomics

264 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Targeted treatment of serious infections mycoBiologics is a University of Aberdeen biotech spinout company which is dedicated to developing new antibody therapies to improve the survival of patients suffering from life-threatening, drug-resistant infections. Antibody therapy, Anti-infectives, Antifungal, Antibacterial, and Drug discovery

298 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Design, Production, and Delivery of Antibodies – Reimagined by AI Genotic utilizes AI for the rapid design and production of customized antibodies for all kinds of targets. Our fully computational, animal-free approach guarantees high quality and delivers solutions within weeks, not years. biotechnology, machine learning, and antibody

247 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: A.I.

Innovative Manufacturing Services (IMFS).

176 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

High-Capacity Gene Therapy Vector Platform to Address Prevalent Diseases Now part of Pacira Biosciences. GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with a single vector, highly efficient gene delivery (high transduction efficiency), and large-scale manufacturability. Based on its HCAd vector platform, GQ Bio develops transformative treatments for chronic, prevalent conditions such as osteoarthritis and intervertebral disc degeneration. GQ Bio is headquartered in Hamburg, Germany and has sites at Luckenwalde (greater Berlin area), Germany and Liège, Belgium. biotechnology, gene …

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Nevezyne develops its own protein expression systems and offers its expertise in the expression of recombinant proteins, for research programs, for diagnosis in animal and human health Protein Expression, Baculovirus System, Protein Purification, and Bacterial System

219 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

e-Zyvec services by Polyplus provide tailor-made plasmids that really fit your needs! e-Zyvec is a French Biotech Start-up founded in 2016 as a spin-off of the University of Lille 1. We are providing unique solutions in molecular biology to academical or industrial scientists working on research project with genetic engineering applications. Using our proprietary DNA assembly technology and our in-house developped web application, we can design and produce fully customized gene expression vectors, fitting exactly the requirements of your project. Getting vectors with e-zyvec is fast, accurate and unrestrictive. Molecular Biology and Genetic Enginnering

59 similar entities Type: Startup Activities: manufacturing deeptech Technologies: Synthetic Biology

IPRASENSE delivers Automated Cell Count & Viability Analyzers as well as time‐lapse imaging/analysis inside incubators IPRASENSE revolutionizes cell analysis with innovative technologies for automated cell counting and real-time visualization, ideal for research and quality control. Cell Count, Viability, Lensless, Holography, Cell Culture Monitoring, High Throughput, low sample volume, Fast count, sample preparation free, Automation Integration, and Label free

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Syndivia is committed to enhancing treatment options for cancer patients with solid tumors by leveraging the distinctive properties of targeted DAR1 antibody-drug conjugates, which offer improved tumor penetration, stability, and efficacy. Drug development, Biotechnology, Pharmaceuticals, Antibody-drug conjugates, DAR1 ADC, and ADC

138 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. biotech, medtech, cell therapy, gene therapy, CAR-T, MSC, iPS, ATMP, Tissue Engineering, cell based therapies, biotherapies, RMAT, and Manufacturing

227 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Viridaxis is a Belgian biotechnology company specialized in the production of beneficial insects used in biological control against crop pests. Active player of the sustainable development, Viridaxis uses a set of advanced technologies in order to offer efficient and environmentally friendly products of excellence. Concerned about the future of the planet and the welfare of its employees, Viridaxis ensures the personal development and motivation of its staff, combining rigor, competence and happiness at work. Passionate about its mission, the entire team of Viridaxis brings to the company all the efficiency, effectiveness and flexibility which makes its worldwide reputation. Parasitoid production, …

38 similar entities Type: SMB Activities: biotech Technologies: Bio sourced materials

Optimizing your gene transfer workflows with GEG Tech technologies GEG Tech is a French Deeptech company specializing in genetic engineering, developing innovative technologies for advanced therapies, including gene therapies, vaccines, cancer immunotherapies and dermatology. GEG Tech designs DNA vectors and has invented a new generation of biological mRNA vectors that are far more efficient than chemical nanoparticles and safer than viral vectors. With 12 years of experience in genetic engineering, the company operates as a studio-lab, serving clients primarily in the United States and Europe. GEG Tech’s scientific team originates from the CNRS, and its laboratory is based on the …

78 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Global Leader in Recombinant Technology for the Life Sciences Sino Biological is a global leader in recombinant protein and antibody production, gene synthesis, and CRO services for life sciences research and drug development. Its facilities include the Center for Bioprocessing (C4B) in Houston, Texas, which specializes in mammalian cell-based protein and antibody production, and SignalChem Biotech (SCB) in Vancouver, Canada, focusing on kinase-related reagents, stable cell line development, and therapeutic discovery. Sino Biological ensures innovative, high-quality solutions for global academic and industrial clients. Recombinant Protein , Elite Antibody , ELISA kits, Gene/cDNA, CRO Service, Biotechnology tools and solutions, ProVir Viral …

155 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Visualize, Connect, and Explore Every Moment of Cellular Research. Incuvers is a hardware + software company developing live cell imaging incubators for cellular researchers. Our flagship product, IRIS (Incuvers Real-time Imaging System) is the most advanced and affordable system for cell culture incubation. Combining hypoxic incubation, live cell imaging, and cloud computing, IRIS lets researchers capture time lapse videos of their entire experiments and monitor them live from anywhere, without ever taking them out of the incubator. The Incuvers mission is to “Visualize, connect, and explore every moment of cellular research”.

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AveXis is now Novartis Gene Therapies Novartis Gene Therapies (formerly AveXis) is reimagining medicine to transform the lives of people living with rare genetic diseases. Utilizing cutting-edge technology, we are working to turn promising gene therapies into proven treatments, beginning with our transformative gene therapy for spinal muscular atrophy (SMA). Follow us on LinkedIn: https://www.linkedin.com/company/novartis-gene-therapies/ How to reach us: Novartis Gene Therapies 2275 Half Day Road, Suite 200 Bannockburn, IL 60015 Email: gtx.communications@novartis.com Office Phone: 847.572.8280 Toll-free Phone: 844.428.3947 Gene Therapy, Synthetic Biology, and Spinal Muscular Atrophy

221 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Fluid Management Equipment Built For You As a global partner to the biopharmaceutical industry, Asahi Kasei Bioprocess helps biologics manufacturers safely and efficiently produce medicines that patients can trust, by dependably supplying innovative yet exceptionally reliable bioprocess consumables, equipment and scientific support services. Our portfolio is anchored by PlanovaTM virus removal filters. First released in 1989 as the world's first hollow fiber filter developed specifically for removing viruses from biotherapeutic drug products, PlanovaTM filters ensure viral safety of biopharmaceutical drug products, thanks to their high quality and consistent performance. Leveraging 30 years of experience, we continue to provide our customers …

88 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Evolution. Adaptation. Future. Phage-based solutions to combat bacteria. - Prevention - Diagnosis - Treatment "One Health" personalized treatments. biotecnología, microbiología, investigación, biomedicina, bacteria, phage, and phage therapy

185 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Beyond LNPs. Beyond the liver. A unique plant-based platform to unlock the potential of RNA therapies beyond vaccination Our mission is to unlock the full therapeutic potential of RNA medicines beyond the limitations of conventional lipid nanoparticles (LNPs) delivery and IVT RNA production systems, especially for in vivo cell-therapy developers. Serendip Innovations is developing a next-generation RNA platform that integrates both RNA manufacturing and targeted delivery beyond the liver. Using a unique plant-based production system and programmable phytovirus-like particles (phytoVLP), we generate functional RNAs directly encapsulated into a proprietary non-viral vector designed for targeted extrahepatic delivery, repeat dosing, and scalable …

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Dream ahead. RIBOPRO is an innovative service provider, producing high-quality, high-performance RNA products, which are used as powerful research tools and therapeutics. RiboPro offers both off-the-shelf and custom RNA products at competitive rates and turn-around times, effectively removing all barriers to successful use of RNA in the research and development of our customers. We have more than a decade of experience satisfying the RNA-related needs of almost 300 customers worldwide and thus we are confident that we can help you get your next project off to a good start. Let us worry about the quality and performance of your RNA, …

59 similar entities Type: Startup Activities: manufacturing deeptech Technologies: Synthetic Biology

Virus and viral vector imaging in living cells applied to antiviral discovery and disinfection processes NeoVirTech (NVT) is one of the leading virus imaging and antiviral discovery company in Europe. The company has been highlighted in the Top10 drug discovery companies, Europe, 2019 by the PharmaTechOutlook Magazine. NVT has developed a breakthrough technology to directly visualize and quantify in real time virus/viral vector infection and replication in living cells, from high resolution to high content imaging. At NeoVirTech, we believe everyone can have access to state-of-the-art virology techniques. We are focusing our activities on antiviral discovery, study of oncolytic and …

68 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A new generation of vaccines based on fusions of recombinant proteins A new generation of vaccines within animal health We develop vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care, with a very good safety profile. Veterinary, Vaccines, Animal Health, Biotech, Recombinant Vaccines, Veterinary Products, Microbiology, Wholesale, and Research and Development

106 similar entities Type: Startup Activities: manufacturing healthtech deeptech Technologies: Synthetic Biology

Cell Signaling Technology for Organ Repair and Regeneration Cell Signaling Technology for Organ Repair and Regeneration We care for liver Our advanced therapy aims to restore liver function thanks to immunomodulatory and regenerative properties of Hepastem Cell therapy, Acquired liver diseases, Liver diseases, liver based genetic diseases, NASH, ACLF, Antibodies, Clinical stage, Chronic liver disease, Fatty liver, Acute liver disease, Regenerative medicine, Biotech, and Biotechnology

94 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pioneering A New Class of Universal Vaccines Osivax is a clinical-stage biopharmaceutical company developing a portfolio of differentiated influenza vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses, thanks to its novel, self-assembling nanoparticle platform technology, oligoDOMTM. The company’s lead candidate, OVX836, is a broad-spectrum influenza A vaccine candidate currently in Phase 2b clinical trials with over 4,000 volunteers tested and encouraging efficacy proof of concept data. By combining OVX836 with standard flu vaccines, Osivax is advancing toward a best-in-class seasonal flu vaccine to prevent all strains of influenza. Osivax collaborates with leading global health agencies …

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Combining expertise and leadership to decrease the global burden of RSV infection. ReSViNET Foundation is the international leading non-profit organization committed to reducing the global burdens of RSV infection. RSV (Respiratory Syncytial Virus) infection is the second most important cause of death during infancy, especially in developing countries. Therefore, research on RSV is crucial. Since the inception in 2014, we have continuously been working to fulfil our Vision and Mission: to decrease the global burden of RSV infection through the advancement of research; providing scientific input; involvement in clinical trials; and organising conferences and offering platforms to share the latest …

50 similar entities Type: Startup Activities: deeptech Technologies: Data Analytics

See how algae moves us. Viridos is a privately held biotechnology company harnessing the power of photosynthesis to create transformative solutions to mitigate climate change. Our unparalleled understanding of algal genetics and ability to translate innovation from lab to field underpins our initial deployment: a scalable platform to produce low-carbon intensity biofuels for aviation, commercial trucking, and maritime shipping. Building on a legacy of genomic firsts, our team of scientists and engineers are shaping new pathways toward a sustainable bioeconomy. To learn more, visit us at Viridos.com. Synthetic Biology, Fermentation, Next Generation Genomics, Bioprocessing, Bioinformatics, Cell Optimization, Biodiscovery, Advanced Engineering, …

60 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Making it possible CLEAN BIOLOGICS is a CDMO for Viral vectors, Viral vaccines and oncolytic viruses and Biosafety testing for biological products. As well as a CMO for MCB & WCB production. GMP compliance

95 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Playing music to cells Kolibri revolutionises the way we grow and engineer cells at scale using acoustic waves. 🔍 Book a discovery call: https://calendly.com/tamsin_kolibrilab/discovery-call Showing 10x increase in cell density and 50x reduction in production costs, our patented bioreactors help our partners in drug development unlock patient access to gene therapies, with a proof of principle in AAV gene therapy. Being cell-agnostic and scalable, our process has significant potential across a range of high-value cell-based therapies - or in the cellular agriculture space more broadly. gene therapy, biomanufacturing, cellculture, acoustics, hardtech, and biotech

385 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Harnessing natural messengers for innovative therapeutics Ciloa is a pioneer in the bioengineering of extracellular vesicles to develop new generations of therapeutics and preventive solutions to improve patients' lives. Ciloa bioengineers sEV proteins, to turn them into natural messengers with huge medical potential. Our bioengineered sEVs can be used as therapeutic solutions in a number of medical fields, including oncology, metabolic diseases, rare diseases and age-related illnesses. Mastering sEV engineering, we have produced sEVs containing a stable, highly multimerised and functional adiponectin (APN), a hormone well known as our “Guardian Angel” for its insulin-sensitizing, anti-inflammatory and anti-oxidative stress properties. Ciloa’s …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The future of vaccines against respiratory infections. Vaxxel develops novel and proprietary live-attenuated vaccines candidate against bronchiolitis and pneumonia and in particular against human Metnapneumovirus and against human Respiratory Virus. Vaxxel is a spin off fom Virpath, the virology and human pathology Laboratory of the University Claude Bernard in Lyon (UCBL), France, and has been founded by Dr. Manuel Rosa-Calatrava Co-Director of Virpath (Lyon), Pr. Guy Boivin of the University of Laval (Quebec), by Denis Cavert, President of Vaxxel. recherche-développement, biotechnologies, santé, and vaccin

64 similar entities Type: Startup Activities: deeptech manufacturing Technologies: Synthetic Biology

Media additives to enhance cell culture systems I IP sold to C-LEcta in Sep 2025. CellRev developed a range of proprietary bioprocessing enzymes to increase yield, improve process consistency, and deliver better manufacturing outcomes. The IP was sold to C-LEcta in September 2025. Bioprocessing, Adherent Cell Culture, Process Engineering, Cell Biology, Cell Growth, and High-Density Processing

109 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

Accelerating drug discovery to transform patients' lives Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com Biopharmaceuticals, Orphan Disease Therapeutics, Rare Diseases, and Serious Diseases

519 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

565 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Provider of cells, 3D tissues and testing services. Epithelix Sàrl is a Swiss biotech company specialized in human tissue engineering. Epithelix provides innovative R&D solutions for the study of human respiratory diseases (e.g. Asthma, COPD, Cystic Fibrosis, etc.) and for inhalation toxicity testing of chemicals, while reducing the number of animal experiments. Human pulmonary toxicology, Preclinical Drug Development, and Human Tissue Reconstitution

59 similar entities Type: SMB Activities: biotech deeptech Technologies: 3D Printing Synthetic Biology

The network of bioproduction biotherapies integrators (RIBB) aims to coordinate, lead and assist the 8 integrators in the field of biotherapies and bioproduction, labeled as part of the “biotherapies and bioproduction of innovative therapies” (SABB) acceleration strategy so that they can respond to their technological platform missions on behalf of academic or industrial partners, and facilitate the industrialization of their technologies/products. Biotherapies, Bioproduction, Cell Therapy, Gene Therapy, and Extracellular Vesicles

209 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

We are now 3PBIOVIAN! Follow us on our new LinkedIn page, 3PBIOVIAN, to stay updated on all the latest developments and news! 3P Biopharmaceuticals and Biovian join forces to create 3PBIOVIAN, a leading pan-European biologics CDMO. Read more here: www.3pbiovian.com ***** 3PBIOVIAN is a globally operating Contract Development and Manufacturing Organization (CDMO), delivering end-to-end services for biotech and pharma companies. Our service offering includes microbial and mammalian protein expression platforms, viral vector production for adenoviruses and adeno-associated viruses, cell therapy, and plasmid DNA production. Additionally, we provide fill and finish services for recombinant proteins and viral vectors. With a combined …

95 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

The first registered vaccine against COVID-19 Sputnik V is the world’s first registered COVID-19 vaccine with proven 91.6% efficacy, based on a human adenoviral vector platform. Registered in over 70 countries.

76 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

Enhancing the transport of therapeutic and imaging agents using versatile and flexible targeting technologies VECT-HORUS, Breaking barriers Vect-Horus designs and develops vectors that facilitate targeting and delivery of therapeutic or imaging agents to organs, including the brain and tumours. Vect-Horus combines these different agents to its vectors that specifically target various receptors, allowing these agents to cross natural barriers (first and foremost the blood-brain-barrier) which limit access of therapeutic or imaging agents to their targets. The proof of concept of the technology has already been established in animal models using different vectorized molecules. Vect-Horus endorces a mixed business model, based …

61 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Based in Paris and in the USA, TheraVectys is an immunotherapy company spun off from the Institut Pasteur created in 2005 by Dr. Pierre Charneau. TheraVectys is pioneering the application of novel lentiviral vector technology to address most of unmet and critical medical needs. By creating the only Joint-Laboratory between a private company and the Institut Pasteur in Paris, TheraVectys develops an extensive pipeline of vaccine candidates to drive the widespread treatment and prevention of cancer and infectious diseases. Leveraging our proprietary technology platform, and the extensive virology expertise of the Institut Pasteur, TheraVectys provides a robust and highly effective …

61 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Translating science into global health impact. Translating scientific discoveries into affordable, globally accessible public health solutions. IAVI is a non-profit that develops vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases. AIDS vaccine, research and development, product development partnership, HIV/AIDS, vaccine development, global health, capacity strengthening, clinical trials, and scientific research

81 similar entities Type: SMB Activities: healthtech deeptech Technologies: Synthetic Biology

Vaccines for the future Based on innovative, patented technology, AIOVA aims to develop and market innovative vaccines, with high added value, to its pharmaceutical industrial clients. AIOVA is positioned in the fight against emerging or re-emerging and deadly pandemics in humans and animals, in a OneHealth approach, and in particular influenza (human and avian flu), AIDS-type diseases, and, very recently, diseases caused by coronaviruses such as SARS-CoV-2, responsible for the current COVID-19 pandemic. The vaccines are designed from a patented DNA platform and have the properties of activating, in the vaccinated host, not only the production of antibodies - which …

60 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Innovative Vaccines for a Healthier World ExpreS2ion Biotechnologies is a clinical-stage DK based biotech company specialised in the development of new vaccines and immunotherapy products. The company has a clinical Phase III-proven discovery platform built around a proprietary recombinant expression system, ExpreS2 TM, developed especially for fast and efficient development and production of complex proteins required for innovative new vaccines, immunotherapy and diagnostics. The system also includes functionally modified glycosylation variants. For the clinical Phase I-stage therapeutic breast cancer vaccine, ES2B-C001, the Company employs a novel plug-&-play capsid virus-like particle (cVLP) platform, that offers competitive advantages in terms of long-term …

63 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Procavea Biotech is on a mission to solve the problem of delivering RNA-based drugs to non-liver tissues. At Procavea we're developing nonviral protein cages as carriers for the delivery of RNA Therapeutics to specific tissues in the body. Protein Engineering and RNA Delivery

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Discover a unique cGMP, in a unique setting, in a unique country. Welcome to FinVector, Kuopio, Finland. Welcome to FinVector, a leading cGMP manufacturer of viral-based products with a strong commitment to restoring hope, purpose and a true sense of belonging for those living with chronic health conditions. FinVector is owned by Ferring Ventures S/A. Learn more: www.finvector.com Instagram: @finvectorians - https://www.instagram.com/finvectorians/ LinkedIn: FinVector Oy - https://www.linkedin.com/company/finvector/ GMP, Manufacturing, Biopharmaceuticals, Gene therapy, and Virus production

59 similar entities Type: SMB Activities: manufacturing deeptech Technologies: Synthetic Biology

Developing technologies for the biopharma industry to allow them to treat the root causes of diseases and disorders. Based in Lausanne, Switzerland, NewBiologix SA is a technology innovation company developing a proprietary and breakthrough DNA integration platform for the advanced engineering of human and mammalian cell lines for the improved production of viral vectors used in gene therapies. gene therapy, cell therapy, next-generation sequencing, NGS, rAAV, viral vectors, biologics, stable cell lines, Genomic Integration, stem cell, bioinformatics, capsid optimization, HEK293, gene expression, ATMPs, genomic, epigenetic, transcriptomic, mammalian cell lines, and human cell lines

206 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Astrivax Therapeutics (Astrivax) is a clinical-stage biopharmaceutical company on a mission to end virus-driven cancer, the second leading preventable cause of cancer after smoking. Its clinically validated Launch-iT platform generates durable, antigen-specific T-cell responses that clear virus-infected cells, supported by a scalable, tech-transfer–ready manufacturing process. Astrivax’s lead program targets human papillomavirus 16 (HPV16), a leading cause of virus-driven cancers, including cervical cancer and head and neck cancer. The company is advancing its platform toward clinical proof-of-concept for persistent HPV infections and plans to expand across additional HPV-driven cancers. Beyond oncology, Astrivax is exploring applications in autoimmune diseases where viral infections …

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Enabling the next generation of medicines Lentivirus is challenging to manufacture. Unwanted transgene expression and viral genome instability are two common and critical issues. Lentitek can help you solve these challenges through a combination of expert design services and the incorporation of our unique manufacturing technology, which effectively eliminates unwanted transgene expression by stabilising the vector genome during the manufacturing process. Our approach enables you to optimise vector performance, enhance quality and safety, and minimise potentially hazardous off-target effects.

64 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Catalyzing Gene Therapy | Revolutionary Technology for Revolutionary Therapies At Fuse Vectors, our mission is to revolutionize AAV gene therapy development. Traditional cell-based technologies have hindered progress, posing challenges in safety, efficacy, development time, and cost. Our Cell-Free AAV technology surpasses these methods, producing safer, more effective, and cost-efficient AAV viral vectors in a fraction of the time.

68 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Accelerating the Development of New Medicines with Targeted Proteomics Inoviv uses a novel technology platform based on targeted proteomics to support pharmaceutical companies with biomarker test development. Proteomics, Biomarker Discovery, Translational Biomarkers, Mass Spectrometry, Targeted Proteomics, Discovery Proteomics, Biomarkers, Precision Medicine, Proteomic Analysis, Proteome Profiling , Quantitative Proteomics, Liquid Chromatography Mass-Spectrometry (LC-MS), Post-Translational Modifications (PTMs), Quantitative Biomarkers, Clinical Proteomics, Immuno-Precipitation Mass Spectrometry (IP-MS), Proteins, LC-MS Proteomics, Proteomics Services, and Protein Identification

178 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Developing Next Generation mRNA Vaccines pHion Therapeutics is a UK based biotech delivering ground-breaking nucleic acid vaccines and therapeutics. The proprietary RALA peptide-based drug delivery system is based on a sequence of 30 amino acids which condenses anionic cargo (RNA and DNA), irrespective of size, into nanoparticles. These nanoparticles are highly efficient at cellular entry with 100% release from the endosomes. When used in vaccines, the RALA platform can deliver multiple anionic molecules, such as mRNA, in a stealth-like way by evading detection. This generates both a potent antigen-specific CD8+ T-cell response that is ideal for therapeutic vaccines, and a …

128 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Enzymatica AB is a Swedish life science company that develops and sells medical devices for infection-related diseases. The products are based on a barrier technology that includes marine enzymes. The Company’s first product is ColdZyme®, a mouth spray which protects against common cold, can help shorten the duration of a common cold if used at an early stage of the infection, alleviates common cold symptoms and soothes sore throat. Our head office is in Lund, Sweden, but we also have an office in Reykjavik, Iceland. For product info, please visit at www.coldzyme.co.uk. Cold and Flu, Enzyme (trypsin), and Barrier technology

219 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Innovative biotechnology company focused on the detection of immune responses to, and diagnosis of, viral diseases. Virax Biolabs is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. medical device development, medical device distribution, Logistics, Procurement, Distribution, IOTH, Innovation, T-Cells, and immunology

78 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Rapid Viral control in a world that needs it Exevir Bio is a biotech company developing efficacious heavy chain-only antibodies to prevent and treat infectious diseases and make a difference in pandemic preparedness. The technology platform of ExeVir uses humanized camelid heavy chain-only antibody fragments (VHH) fused to a human IgG Fc to create new therapeutic compounds. ExeVir is building a strong pipeline of antibody therapies with an initial focus on COVID-19 and dengue. Compared to conventional monoclonal antibodies, the modular VHH building blocks provide a unique combinatory flexibility. In addition, the design of multi-specific constructs is substantially simplified. VHHs …

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

UV-C High-Level Disinfection for endocavitary and external ultrasound probes Germitec’s mission is to protect patients, healthcare professionals and prevent infections with innovative UV-C High Level Disinfection devices. Our products uses patented Yuvee® UV-C technology to provide High-Level Disinfection (HLD) for endocavitary and external ultrasound probes. ultrasound, disinfection, highleveldisinfection, infectioncontrol, ultraviolet, UVC, HLD, transducers, HPV, hightech, medtech, greentech, cleantech, frenchtech, healthtech, innovation, patientsafety, and infectionprevention

64 similar entities Type: SMB Activities: deeptech manufacturing Technologies: Synthetic Biology

We are a specialist respiratory biotech company focused on severe viral lung infections Synairgen is a specialist respiratory biotech company whose primary focus is developing its investigative inhaled IFN-β candidate for the treatment of severe viral lung infections as potentially the first host-targeted broad-spectrum antiviral treatment delivered directly into the lungs. Founded by University of Southampton (UK) Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information, please visit www.synairgen.com.

73 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Protein Sciences (www.proteinsciences.com) is a biotechnology company that specializes in vaccine development and protein production. Our mission is our inspiration: to save lives and improve health by effectively responding to the changing world through the creation of innovative vaccines and biopharmaceuticals. See where Flublok® Influenza vaccine is available at www.flublok.com. We use our proprietary BEVS protein expression technology to produce high quality recombinant proteins quickly, reliably and at low cost. We have developed three main business lines that employ this technology: 1. Proprietary vaccines - we develop and produce the next generation of safer and more effective vaccines 2. GeneXpress® …

133 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Exosome-based therapeutics Exogenus Therapeutics is an innovative biotech start-up dedicated to early stage development of therapeutic tools. Using an exosome-based platform technology, Exogenus is developing biologic products for diseases with high unmet needs, such as inflammatory and autoimmune diseases. Driven by the urgency imposed by the COVID-19 pandemic, the company is currently developing solutions for the treatment of severe lung inflammation, a condition with limited treatment options and a common cause of death following SARS‐CoV‐2 infection. Contact us at team@exogenus-t.com Biotechnology, Regenerative Medicine, Stem cells, exosomes, cell biology, and therapies

293 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics

296 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

a wholly owned subsidiary of Eli Lilly and Company LimmaTech Biologics AG, a wholly owned subsidiary of Eli Lilly and Company, is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. vaccines, research & development, biotechnology, and antimicrobial resistance

419 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We’re using ground-breaking cell technologies to revolutionise global food production - starting with pork Uncommon Bio began with cell-based meat and pioneered RNA delivery innovations, which evolved into their most recent spin out which is focusing on changing medicine through multi-targeting. Their polysaccharide-based delivery platform enables multi-pathway cell programming, offering a safe, efficient and scalable alternative to multi-target therapies. The company is initially targeting severe lung diseases like idiopathic pulmonary fibrosis and is backed by industry leaders from BioNTech and top investors, including Sam Altman, Balderton, Lowercarbon, and Redalpine. science+art, biotech, mRNA, IPF, Pulmonary fibrosis, and delivery

561 similar entities Type: Startup Activities: biotech deeptech foodtech Technologies: Synthetic Biology

Aeras is a non-profit biotech advancing the development of tuberculosis vaccines for the world. In collaboration with global partners in Africa, Asia, North America and Europe, Aeras is supporting the clinical testing of six experimental vaccines as well as a robust portfolio of earlier stage candidates. Aeras receives funding from the Bill & Melinda Gates Foundation, the UK Department for International Development, and the Netherlands’ Ministry of Foreign Affairs and a range of other governments. Aeras is based in Rockville, Maryland; Cape Town, South Africa; and Beijing, China. tuberculosis, vaccines, clinical trials, vaccine manufacturing, and HIV

59 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Innovative biotech company developing next generation of cell culture systems designed to revolutionize biomanufacturing Cellevate develops and markets products based on a proprietary nanofiber-based platform - the Cellevat3dTM - with the potential to revolutionize upstream bioprocessing from R&D to commercial manufacturing. Our latest product line in development – Cellevat3dTM carriers – with a commercial launch planned for 2024, provides extracellular-like environments with exceptional surface areas for adherent cell cultures. Initial results show tremendous potential to increase yields, minimize risk and reduce costs in development and manufacturing. We offer a range of products based on our versatile and easily functionalized platform …

179 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Multipathogen Vaccines To Protect Against Respiratory Viruses Vicebio is a clinical-stage biopharmaceutical company developing transformative multi-pathogen vaccines for respiratory viral infections. At the core of our work is Vicebio’s groundbreaking Molecular Clamp Technology, which locks viral proteins in their optimal conformation. This innovation enables our vaccines to deliver a unique combination of broad protection, ready-to-use administration, and convenient manufacturing. Our lead program is a best-in-class multivalent vaccine targeting five respiratory diseases, positioning Vicebio as a leader in multipathogen respiratory vaccines. Vaccines, Structural vaccinology, respiratory viruses, RSV, Influenza, SARS-Cov-2, Metapneumovirus, and Parainfluenza

65 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Ilya Pharma 🇸🇪🇺🇸 is bringing local-acting immunotherapies to patients Delivering local-acting immunotherapies to patients ATMP, Gene Therapy, Drug development, Clinical trials, GMP, IBD, Wound treatment, Scar, Topical, Oral, Research, Science, Immunology, Immunophysiology, microbiology, Applied microbiology, Regulatory excellence, Skin, Diabetes, IBD, Cysticfibrosis, SAVI, colitis, Cystic fibrosis, and Inhalation

646 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Develop human organ models with true physiological complexity We are specialized in the production and development of human, immunocompetent Organ-on-Chip technology for in vitro disease and infection modelling. Organ-on-Chip, Human Cell Biology, Infection, Infectious disease, Toxicity profiling, Immune Cell Interactions, Inflammatory Diseases, Antibody recycling, and Uptake / Transport studies

263 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

Applying AI to drug discovery Evariste is an AI-enabled drug discovery company developing small molecule inhibitors of next generation synthetic lethality targets. Using our automated AI-enabled drug discovery platform, Frobenius, we are able to progress preclinical drug discovery projects at scale and with unparalleled efficiency. Technology , Software, Biotech, Research, and Drug Discovery

209 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I.

Discovery of innovative therapeutic antibodies for human and animal health MabGenesis is a biopharmaceutical startup that delivers first-in-class and best-in-class therapeutic monoclonal antibodies using technologies established by 30+ years of academic research. By using the innovative technology platform, high-quality phage display antibody libraries (MOURA Libraries) and efficient antibody isolation technology (IMPACT), MabGenesis makes it possible to isolate 100% species-specific monoclonal antibodies rapidly and efficiently. MabGenesis is a private company headquartered in Yokohama, Japan. For more information, visit https://mabgenesis.com/en Biotechnology, Antibody, Monoclonal antibody, VHH, membrane protein, Canine, Feline, GPCR, Autoimmune diseases, Cancer, Inflammatory diseases, Phage display antibodies, and Antibodydiscovery

65 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Dare to Discover - Precision DNA & RNA services to accelerate cell, gene, and RNA therapies development. At Officinae Bio we're developing a platform to support the future of biologically designed therapeutics. By developing breakthroughs in AI-enabled methodologies for nucleic manufacture we’re supporting pioneering research in Gene-modified Cell therapy, Gene therapy and RNA therapeutic research. DNA platform An automated platform for streamlined development of plasmids and libraries for viral vector and mRNA. RNA platform Our industry leading mRNA development and manufacturing solutions support rapid turnaround, advanced transcription capabilities and precision control over regulatory sequences design. Artificial Intelligence, RNA synthesis, In …

98 similar entities Type: Startup Activities: manufacturing deeptech Technologies: A.I.

Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel multispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly owned clinical assets, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas. For more information, email info@dragonflytx.com. immuno-oncology

94 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We Use Small Molecules To Modify RNA Splicing Skyhawk Therapeutics is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that modify RNA expression. Our founders are leading experts in small molecule therapeutics development for RNA-based disease. Our first drug candidates are targeted toward cancers and neurological conditions. The company is based in Waltham, Massachusetts. For more information, please visit: www.skyhawktx.com.

281 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leveraging genetics to treat neurological diseases Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACERTM AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs …

159 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading the way in targeted protein degradation therapeutics Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its PROTAC Discovery Engine to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting estrogen receptor for patients with locally advanced or metastatic ER+/HER2- …

65 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Better Access. Better Lives. Our mission is to improve patient lives and the sustainability of the global healthcare ecosystem by broadening the availability and accessibility of biosimilars. Biopharmaceuticals, Research and Development, Biosimilars, Biotechnology, Pharmaceutical, Biogenerics, Health, Cell Line Development, Business Development, and Regulatory

418 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Best-in-class viral vector and nucleic acid development and manufacturing services Exothera is a contract research, development, and manufacturing organization (CDMO) dedicated to viral vector and nucleic acids production. As a technology-driven company, Exothera provides best-in-class bioprocessing expertise that capitalizes on the best and most innovative manufacturing technologies developed within the Univercells group. The company delivers accelerated discovery services as well as process development/optimization to rapidly reach GMP clinical and commercial production of viral vectors and nucleic acids. At Exothera and Univercells, Our mission is to make life-changing therapies available to all. As a Univercells company, Exothera capitalizes on novel manufacturing …

72 similar entities Type: Startup Activities: deeptech biotech manufacturing Technologies: Synthetic Biology

Discovery through DNA Wilderlab is an ISO-accredited, commercial environmental DNA (eDNA) testing lab operating in Wellington, Sydney and Seattle. Wilderlab offers a robust and accessible eDNA service for addressing a wide range of monitoring needs, including biodiversity, conservation, ecosystem health assessments, biosecurity, and pathogen surveillance. With Wilderlab’s technology, anyone can make exciting and meaningful discoveries with eDNA! eDNA, metabarcoding, bioinformatics, environmental DNA, and eDNA kits

52 similar entities Type: Startup Activities: deeptech healthtech

Get results faster, when it matters most. It’s so much more than a specimen. It's a life. With over 30 years of specialized expertise in infectious disease, immunology, transplant, and allergy testing for immunocompromised and critical patients, Eurofins Viracor is committed to helping medical professionals, transplant teams, reference labs and biopharmaceutical companies get results faster, when it matters most. Eurofins Viracor is passionate about providing timely, actionable test results, never losing sight of the connection between the testing we perform and the patients our results ultimately serve. Follow us on Bluesky: @eurofinsviracor.bsky.social Eurofins Viracor is an equal opportunity employer. Infectious …

69 similar entities Type: SMB Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Novalix is a premier drug discovery CRO Novalix is a premier drug discovery partner to biotech firms and pharmaceutical companies. We apply our exceptional scientific talent and exclusive resources across our platforms to improve the odds of success at each critical pre-clinical stage. The better the science, the better the outcomes. For additional information visit www.novalix.com Target based drug discovery, NMR, SPR, Epigenetic targets, Nuclear receptors, Protein-ligand co-crystal structures by XRD, Native mass spectrometry, FBDD, Organic Chemistry, cryo-electron microscopy, Chemical development, Medicinal chemistry, Structural Biology, in vitro pharmacology, DNA-encoded libraries, Flow chemistry, Chemical process research, DMPK, and ADME

515 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Discovering & developing novel anti-infectives to treat multi-drug resistant bacterial & hard-to-treat viral infections. Venatorx Pharmaceuticals is a private pharmaceutical company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. antibiotics, antiinfectives, antivirals, drug development, drug discovery, pharmaceuticals, #battlesuperbugs, #WorkingToFightAMR, clinical, research, #squashsuperbugs, biotech, and antimicrobialresistance

91 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Interventions for Human Diseases Venture-funded company, discovering and developing oral novel small molecule first-in-class inhibitors of Bach1 (a transcription factor) as transformative potential therapy, globally accessible for patients with sickle cell disease (SCD), renal, cardiometabolic and neurodegenerative and other diseases. Sickle Cell Disease, fetal hemoglobin induction, beta-thalassemia, Renal diseases, cardiometabolic diseases, and neurodegenerative diseases

184 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration with CSL Seqirus, U.S. BARDA for …

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

miRNA-enhanced Extracellular Vesicles Therapeutics ConvEyXO, founded in 2019 by veterans of pharma industry, builds a specialized technology platform to convey exosome-based therapeutics to the market. The company is developing is therapeutic portfolio in the field of fibrosis and chronic inflammatory disorders. The rapid development of the company is the result of collaborations with partners with a demonstrated track record in healthtech and biotech fields manufacturing, process development, upstream, downstream, extracellular vesicles, exosomes, therapeutics, cargo, Loading, 4D, and exosomes

444 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing RNA's technologies Desarrollamos tecnologías basadas en ARNs con el fin de potenciar la productividad de los cultivos (principalmente intensivos) de manera respetuosa del ambiente y la salud humana. Se trata de una tecnología no transgénica que permite inmunizar a los cultivos contra patógenos específicos (hongos, insectos, virus), a modo de “vacuna”. Además, sabemos cómo modular el desarrollo del cultivo, su respuesta al ambiente o la acumulación de metabolitos de interés mediante el diseño de ARNs como moléculas bioactivas exógenas que modulen la expresión de genes de la planta. Acelerados por EIT FAN de la Unión Europea Fruits, Biotech, RNA, …

107 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Building Better Biology At MarraBio we design, engineer and construct bacterial protein polymers, that contain the biological messages that cells need to grow, divide and behave properly. Cells grown on an industrial scale for research, agricultural or therapeutic use need to be supplied with the right signals. We provide a multi-functional, cost effective solution in a single, easy to use material. Find out more at https://www.marrabio.com/ Protein Engineering, Protein Production, Cellular Agriculture, Cultivated Meat, Research Reagents, Stem Cell Expansion, and Industrial Scale Cell Culture

351 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology